We observed that the combination of IL-33 and anti-PD-1 antibody significantly drives anti-tumor responses toward melanoma by promoting ILC2s and cytotoxic eosinophil infiltration into tumors [60]. This evidence concerns the gene PDCD1 and neoplasm.